CA2709994A1 - Affichage alternatif de phage de fusion de proteine de support par la fusion en plx du phage m13 - Google Patents

Affichage alternatif de phage de fusion de proteine de support par la fusion en plx du phage m13 Download PDF

Info

Publication number
CA2709994A1
CA2709994A1 CA2709994A CA2709994A CA2709994A1 CA 2709994 A1 CA2709994 A1 CA 2709994A1 CA 2709994 A CA2709994 A CA 2709994A CA 2709994 A CA2709994 A CA 2709994A CA 2709994 A1 CA2709994 A1 CA 2709994A1
Authority
CA
Canada
Prior art keywords
protein
phage
antibody
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2709994A
Other languages
English (en)
Inventor
Steven Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Ortho Biotech Inc.
Steven Jacobs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc., Steven Jacobs filed Critical Centocor Ortho Biotech Inc.
Publication of CA2709994A1 publication Critical patent/CA2709994A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
CA2709994A 2007-12-19 2008-12-19 Affichage alternatif de phage de fusion de proteine de support par la fusion en plx du phage m13 Abandoned CA2709994A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1477807P 2007-12-19 2007-12-19
US61/014,778 2007-12-19
PCT/US2008/087696 WO2009086116A2 (fr) 2007-12-19 2008-12-19 Affichage alternatif de phage de fusion de protéine de support par la fusion en plx du phage m13

Publications (1)

Publication Number Publication Date
CA2709994A1 true CA2709994A1 (fr) 2009-07-09

Family

ID=40825038

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2709994A Abandoned CA2709994A1 (fr) 2007-12-19 2008-12-19 Affichage alternatif de phage de fusion de proteine de support par la fusion en plx du phage m13

Country Status (6)

Country Link
EP (1) EP2238247A2 (fr)
JP (1) JP2011507529A (fr)
AU (1) AU2008345674A1 (fr)
CA (1) CA2709994A1 (fr)
IL (1) IL206409A0 (fr)
WO (1) WO2009086116A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
WO2009102421A2 (fr) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Agents thérapeutiques cibles basés sur des protéines fabriquées qui se lient au récepteur de l’egf
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
PL2356269T3 (pl) 2008-10-31 2016-12-30 Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
EP3569256B1 (fr) * 2010-04-30 2022-06-15 Janssen Biotech, Inc. Compositions de domaine de fibronectine stabilisées, procédés et utilisations
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
PT2697257T (pt) 2011-04-13 2016-12-28 Bristol Myers Squibb Co Proteínas de fusão fc compreendendo novos ligantes ou arranjos
EP2709669A1 (fr) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Procédés de maintien de la pegylation de polypeptides
EP3318880B1 (fr) 2011-05-17 2020-12-16 Bristol-Myers Squibb Company Procédés améliorés pour la sélection de protéines de liaison
EP3540100B8 (fr) 2011-09-27 2022-11-02 Janssen Biotech, Inc. Échafaudage de protéine à base de répétition de fibronectine de type iii avec des surfaces de liaison alternatives
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
CN104768969B (zh) 2012-09-13 2021-04-16 百时美施贵宝公司 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP3406629B1 (fr) 2013-02-06 2020-06-24 Bristol-Myers Squibb Company Protéines du domaine de la fibronectine de type iii à solubilité améliorée
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
WO2014126871A1 (fr) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company Procédés de repliement de protéine utilisant la filtration tangentielle
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP2968587A2 (fr) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Domaines d'échafaudage à base de fibronectine liés à une sérum albumine ou fragment se liant à celle-ci
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
MX2016011580A (es) 2014-03-20 2016-11-29 Bristol Myers Squibb Co Dominios de fibronectina tipo iii que se unen a albumina de suero.
EP3647322B1 (fr) 2014-03-20 2021-10-20 Bristol-Myers Squibb Company Molécules de charpente à base de fibronectine stabilisée
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
EP3708580B1 (fr) 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Domaines de la fibronectine de type iii se liant à l'albumine sérique à vitesse de dissociation élevée
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US10626165B2 (en) 2016-12-14 2020-04-21 Janssen Biotech, Inc. CD8a-binding fibronectin type III domains
EP3554535A4 (fr) 2016-12-14 2020-10-21 Janssen Biotech, Inc. Domaines de fibronectine de type iii se liant à pd-l1
WO2018111978A1 (fr) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Domaines de fibronectine de type iii à liaison au cd137
US11628222B2 (en) 2019-10-14 2023-04-18 Aro Biotherapeutics Company CD71 binding fibronectin type III domains
WO2021076574A2 (fr) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Conjugués domaine fn3-arnsi et leurs utilisations
JP2023515633A (ja) 2020-02-28 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー 放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148263A1 (en) * 1997-08-29 2003-08-07 Selective Genetics, Inc. Methods and compositions using genetic package display

Also Published As

Publication number Publication date
AU2008345674A1 (en) 2009-07-09
IL206409A0 (en) 2010-12-30
WO2009086116A2 (fr) 2009-07-09
EP2238247A2 (fr) 2010-10-13
WO2009086116A3 (fr) 2009-10-08
JP2011507529A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
CA2709994A1 (fr) Affichage alternatif de phage de fusion de proteine de support par la fusion en plx du phage m13
JP4829457B2 (ja) 抗体模倣物および他の結合タンパク質のタンパク質骨格
Clackson et al. In vitro selection from protein and peptide libraries
AU2004242851B2 (en) Generation of artificial binding proteins based on ubiquitin proteins
US5625033A (en) Totally synthetic affinity reagents
JP5868346B2 (ja) 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
EP0774118B1 (fr) Triages specifiques de cibles et leur utilisation permettant la decouverte de petits groupements pharmacophores moleculaires organiques
US20100021477A1 (en) DESIGN AND GENERATION OF HUMAN DE NOVO pIX PHAGE DISPLAY LIBRARIES
US20020137053A1 (en) Collections of binding proteins and tags and uses thereof for nested sorting and high throughput screening
AU2001241850A1 (en) Protein scaffolds for antibody mimics and other binding proteins
CN105247050B (zh) 用于文库构建、亲和力结合剂筛选和其表达的整合系统
US20030143612A1 (en) Collections of binding proteins and tags and uses thereof for nested sorting and high throughput screening
WO2014100419A1 (fr) Compositions et méthodes pour identifier et isoler des fragments de liaison spécifiques de protéines de membranes cellulaires
US8728982B2 (en) Engineered hybrid phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pIX of M13 phage
JP2020534796A (ja) エピトープ翻訳後修飾状態に特異的な抗体の開発方法及び開発のための組成物
Mandecki et al. Phage Display and Selection of Protein Ligands
Liotta Hot Methods Clinic: PHAGE EPITOPE DISPLAY LIBRARIES
AU2769002A (en) Target specific screens and their use for discovering small organic molecular pharmacophores
AU5713899A (en) Target specific screens and their use for discovering small organic molecular pharmacophores

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20121219